Hospital Británico

Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy

BackgroundSavolitinib is an oral, potent, highly selective MET–tyrosine kinase inhibitor (TKI). Combination therapy with savolitinib and osimertinib, an epidermal growth factor receptor (EGFR)–TKI, has shown activity in patients with EGFR-mutated, advanced non–small-cell lung can...

The Global Airways Unit: A Multidisciplinary Strategy for Early Diagnosis and Comorbidity Detection

ABSTRACT Background Chronic respiratory diseases impose a large global burden of morbidity, mortality, and cost. The concept of a global airway has become increasingly supported by epidemiologic, mechanistic, and clinical evidence. However, clinical care often remains fragmented...